Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setrusumab Phase 2a in Adults with OI
NCT01417091Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jun 2011
- Primary completion
- Dec 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of setrusumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Safety and tolerability (composite outcome: standard laboratory, (serious) adverse events), Determination of pharmacodynamic effect by means of biomarkers at Day 43 and 1 more. Started Jun 2011; status: completed.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT01417091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417091.